Danaher adds two directors, expands board to 13 members

Danaher Corporation (NYSE: DHR) appointed Daniel L. Comas and Robert Hershberg, M.D., Ph.D., to its board of directors on October 9, 2026, according to a company press release. The board was expanded from 11 to 13 directors to accommodate the appointments.

Comas joined Danaher in 1991 and served as Executive Vice President from April 2005 through December 2020, including as Chief Financial Officer from April 2005 through December 2018. He later served as a senior advisor and consultant to the company through September 2026. He also serves as a director of Fortive Corporation and Veralto Corporation.

Hershberg served as President, Chief Executive Officer and Chairman of HilleVax, Inc. from March 2020 through September 2025, and previously held senior roles at Celgene Corporation, including Executive Vice President and Chief Scientific Officer. He has also been appointed to Danaher's Science and Technology Committee. He currently serves as a Senior Advisor to Frazier Life Sciences and as a director of Adaptive Biotechnologies Corporation and Recursion Pharmaceuticals, Inc.

Board member Alan G. Spoon will not stand for reelection at Danaher's 2027 Annual Meeting of Shareholders, retiring from the board at that time.

Separately, Danaher co-founders Steven and Mitchell Rales each waived their right to 500,000 restricted stock units from awards granted to them on August 4, 2026.

You May Also Be Interested In

• StoneX Starts SoFi Technologies (SOFI) at Buy
• CME Group hits cloud migration milestones ahead of schedule
• Murphy Oil reports drilling success in Côte d'Ivoire, Vietnam, and Gulf